Abstract collections occupy a distinctive place in biomedical publishing. Unlike a conventional review or original research article, an abstract supplement is a snapshot of work in progress: hundreds of concise summaries, each typically describing a single study, case series, quality-improvement project, or technological innovation. The format trades depth for breadth and immediacy. A reader can scan the entire landscape of a field in a single sitting, identifying which questions are attracting attention, which methods are gaining traction, and where the field’s energy is heading. For meeting attendees, the collection functions as a companion volume to the oral and poster sessions; for those who cannot attend, it offers a structured window into conversations they would otherwise miss entirely.

Neurocritical care itself is one of the youngest subspecialties in medicine, and its rapid maturation is part of what makes annual abstract collections from the society so closely watched. The field emerged from the recognition that patients with severe brain injury, whether caused by trauma, stroke, hemorrhage, seizures, or infection, require intensive management that addresses not only the primary insult but also the secondary injuries that unfold in the hours and days afterward. Elevated intracranial pressure, disrupted cerebral blood flow, metabolic derangements, and inflammation can each compound the original damage. Preventing those secondary insults is the central task of the neurocritical care unit, and it demands expertise that spans neurology, neurosurgery, anesthesiology, emergency medicine, nursing, and pharmacy.

The scope of work typically presented at the society’s meetings reflects that interdisciplinary character. In past cycles, abstracts have ranged from clinical trials and large observational cohort analyses to bedside physiology studies, investigations of novel monitoring technologies, surveys of practice variation across institutions and countries, and analyses of outcomes and health equity. Quality-improvement and implementation science projects are well represented as well, since translating evidence into consistent bedside practice remains one of the field’s persistent challenges. The 2026 abstracts continue this tradition, gathering contributions from investigators at every career stage, including a substantial share from trainees whose first scientific presentations often begin as meeting abstracts.

For researchers, the publication of meeting abstracts in a peer-reviewed journal serves several practical functions. It establishes priority by timestamping an idea or finding in the permanent record. It allows the work to be cited while the full manuscript is being prepared, which matters enormously in fast-moving areas where a two-year lag between meeting presentation and journal publication can render a finding stale. It also provides early-career investigators with a citable entry on their records at a stage when authorship on a full paper may still be months or years away. Journals in the field, including Neurocritical Care, have long treated these supplements as an integral part of their annual publishing cycle rather than an afterthought.

Readers and clinicians, meanwhile, use abstract collections in a different way: as a forecasting tool. Patterns across hundreds of summaries can reveal where consensus is forming and where controversy persists. When multiple groups from different countries independently report on the same question in the same year, that convergence often signals that a shift in practice or in trial design is imminent. Conversely, persistent disagreement across abstracts can highlight areas where the evidence base remains thin and where large collaborative studies are needed. Meeting abstracts therefore function as an informal but valuable barometer of the field’s direction, one that complements the slower and more definitive signal of fully published trials.

The twenty-fourth annual meeting arrives at a moment of genuine ferment in brain injury medicine. Questions about how best to monitor the injured brain, how to individualize targets for blood pressure, oxygenation, and intracranial pressure, and how to integrate artificial intelligence and advanced analytics into bedside decision-making are all active areas of investigation across the neurocritical care community. Multicenter collaboration has become increasingly central to the field’s progress, because many of the conditions it treats, while devastating for individual patients, are individually rare enough that no single institution can recruit adequate numbers for definitive studies. Annual meetings and their published abstracts are where those collaborations are forged, refined, and announced.

It is worth emphasizing what an abstract collection is not. The summaries in a supplement have typically undergone review for relevance and scientific soundness, but they are not full peer-reviewed papers, and their findings should be regarded as preliminary until they survive the more demanding scrutiny of a complete manuscript. Sample sizes in abstracts are often small, analyses are sometimes interim, and conclusions are appropriately hedged. Responsible reporting and reading of these collections means treating each summary as a hypothesis-generating contribution to an ongoing conversation rather than as settled evidence. That caution applies with particular force to any abstract touching on treatment effects, where premature changes in practice based on preliminary data can do real harm.

Even with those caveats, the appearance of the 2026 abstracts in Neurocritical Care marks the formal opening of the scientific record for the society’s twenty-fourth annual meeting. Clinicians and scientists can now locate, cite, and build upon the work presented there, and the wider public can glimpse the questions that the specialists who care for patients with the most severe neurological injuries are asking next. The full articles that many of these abstracts will become are already in preparation in laboratories and clinical research units around the world, and over the coming months and years they will carry the field’s findings from the meeting hall to the bedside. For a subspecialty defined by the race against secondary brain injury, that pipeline from preliminary result to validated practice is not an administrative detail. It is the mechanism by which the discipline improves, one meeting, one abstract, and one published paper at a time.

Subject of Research: Publication of the Neurocritical Care Society's 24th Annual Meeting 2026 abstracts in the journal Neurocritical Care

Article Title: Neurocritical Care Society Abstracts from the 24th Annual Meeting 2026

Article References: Neurocritical Care Society Abstracts from the 24th Annual Meeting 2026. (2026). Neurocritical Care. https://doi.org/10.1007/s12028-026-02638-5

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02638-5

Keywords: neurocritical care, Neurocritical Care Society, annual meeting, conference abstracts, brain injury, Springer Nature, medical publishing, intensive care, clinical research, scientific meetings, Neurocritical, Care

The new guideline represents a substantial methodological step forward. Where the 2016 document relied on more traditional evidence appraisal, the update applies stringent Grading of Recommendations Assessment, Development, and Evaluation criteria, the current international standard for evaluating the certainty of medical evidence. The authors also performed formal meta-analyses, pooling data across studies to generate more precise estimates of benefit and harm. Five specific questions, framed in the PICO format of population, intervention, comparison, and outcome, structured the effort: whether andexanet alfa outperforms prothrombin complex concentrates for reversing direct factor Xa inhibitors; whether desmopressin helps patients on antiplatelet drugs; whether platelet transfusion improves outcomes; whether coagulopathy reversal benefits patients with very small hemorrhages; and whether viscoelastic hemostatic testing, such as thromboelastography and rotational thromboelastometry, meaningfully improves mortality, functional recovery, thrombosis rates, hemorrhage expansion, or treatment-related adverse events. Recommendations were further stratified by whether the bleeding was spontaneous or traumatic, an important distinction that reflects growing recognition that these two patient populations behave differently.

Notably, the update deliberately left many of the 2016 recommendations untouched. Reversal strategies for vitamin K antagonists such as warfarin, direct thrombin inhibitors, unfractionated heparin, low molecular weight heparin, pentasaccharides, and thrombolytics were not re-reviewed, largely because no compelling new literature had emerged that would substantively alter the prior guidance. That decision itself carries information: a decade of research has reshaped thinking in some corners of antithrombotic reversal while leaving others remarkably stable. The most dramatic shifts concern the factor Xa inhibitor antagonists, the class of oral anticoagulants that includes apixaban and rivaroxaban and that has steadily displaced warfarin in clinical practice.

The spotlight falls squarely on andexanet alfa, a recombinant decoy protein engineered to bind factor Xa inhibitors in the bloodstream and neutralize their anticoagulant effect. Early enthusiasm was fueled by the ANNEXA-4 study, which demonstrated that andexanet effectively reduced expansion of intraparenchymal hematomas. Yet adoption was hampered from the outset by the drug’s extraordinarily high cost, and Frontera’s own prior work quantified just how stark the price gap is compared with prothrombin complex concentrates, the four-factor blood products that have long served as the workhorse reversal agent. The pivotal test arrived with ANNEXA-I, a randomized trial that pitted andexanet against usual care, with 86 percent of the comparator group receiving prothrombin complex concentrates. Andexanet achieved significantly better hemostatic efficacy, but that win came with a sobering price: a 5 percent absolute increase in thrombotic events within 30 days, driven particularly by ischemic strokes. Mortality and functional outcomes showed no difference between the arms, leaving clinicians facing an uncomfortable question about which harm matters more, ongoing hematoma expansion or a treatment-emergent ischemic stroke.

The new guideline’s meta-analyses sharpened that trade-off into hard numbers. Pooling the available data suggested a modest but statistically significant 9 percent relative improvement in hemostatic efficacy for andexanet over prothrombin complex concentrates. Against that benefit stood a significant 35 percent relative increase in thrombotic events. Further meta-analyses found no mortality or functional outcome advantage for andexanet, and, perhaps most strikingly for health systems, both hospital and intensive care unit lengths of stay were longer when andexanet was used. The pharmacology helps explain the thrombosis signal: andexanet does not simply remove apixaban or rivaroxaban from the body, it floods the circulation with inert decoys that also bind endogenous tissue factor pathway inhibitor, transiently unleashing coagulation beyond the point of simple reversal. Weighing all of this, the Neurocritical Care Society recommendation now diverges sharply from its European counterpart, the European Stroke Organisation and the European Association of Neurosurgical Societies, whose expert consensus still suggests considering andexanet in adults with spontaneous intracranial hemorrhage on factor Xa inhibitors who present within 15 hours of their last dose, or with proven anti-factor Xa activity above 100 nanograms per milliliter, and within 12 hours of symptom onset. Frontera notes that the European position rests primarily on the ANNEXA-I trial alone, whereas the North American guideline synthesized multiple meta-analyses. The situation is further complicated by market reality: andexanet is no longer available in the United States as of December 2025, though it remains accessible elsewhere in the world, meaning that international practitioners must still navigate these conflicting recommendations at the bedside.

A second provocative question addressed by the guideline is whether anticoagulation reversal should be abandoned for very small hemorrhages, defined here as an intraparenchymal hematoma volume of 10 milliliters or less. The intuition seems reasonable: if a bleed is tiny, perhaps the risks of procoagulant reversal, including thrombosis, outweigh any benefit. But the trial data undercut that logic in an unexpected way. The median hematoma volume in ANNEXA-I was only 10 milliliters, and just 13 milliliters in the earlier INCH trial of vitamin K antagonist reversal. Both studies demonstrated improvements in laboratory measures of coagulopathy and reductions in hematoma expansion, suggesting that even small hemorrhages benefit from reversal. Paradoxically, the data gap lies at the other end of the spectrum: patients with very large hemorrhages were typically excluded from randomized trials, so clinicians managing the sickest patients have the least rigorous evidence to guide them.

The biology of hemorrhage location adds another layer of nuance. The same volume of blood wreaks very different degrees of damage depending on where it accumulates in the brain. A recent analysis cited in the commentary identified volume thresholds that predict poor 90-day outcomes, defined as modified Rankin scores of 4 through 6, and found that the critical threshold is substantially lower for deep hemorrhages, at 17 milliliters or more, than for lobar hemorrhages, at 36 milliliters or more. A deep bleed near critical structures such as the brainstem can be catastrophic at volumes that would be survivable in a lobar location. In other words, even modest expansion of a small deep hemorrhage could translate into substantially worse functional outcomes, which strengthens the argument that initial volume alone should not determine whether reversal is offered. Timing matters too: the time from last known well and the time since the last antithrombotic dose are key predictors of expansion, as are imaging biomarkers such as the spot sign on contrast-enhanced CT, which identifies active extravasation.

The temporal dynamics of risk provide perhaps the most persuasive clinical argument in the commentary. Within the first 48 hours after an intracerebral hemorrhage begins, the risk of hematoma expansion dwarfs the thromboembolic risk of temporarily stopping antithrombotic therapy. The danger of ischemic events off anticoagulation rises only in a delayed fashion, after several days. Even patients at extremely high thromboembolic risk, including those with mechanical heart valves and left ventricular assist devices, appear to tolerate anticoagulation reversal well, with low thromboembolic rates during the first 7 to 14 days after hemorrhage onset. Given that these are the very patients for whom clinicians most fear withholding anticoagulation, the evidence suggests the acute reversal decision can be made with relative confidence. Although the guideline authors judged the data insufficient to issue a formal recommendation on reversal for small-volume hemorrhages, Frontera argues that offering reversal in the acute window, when expansion risk peaks, is prudent regardless of initial volume or the original indication for anticoagulation.

The final significant shift concerns desmopressin, commonly known as DDAVP, a vasopressin analog that increases circulating levels of von Willebrand factor and factor VIII and has been proposed as a hemostatic agent for patients bleeding while on antiplatelet drugs such as aspirin and clopidogrel. The 2016 guideline had conditionally recommended DDAVP on the basis of low-quality evidence. Applying rigorous GRADE criteria to the accumulated data, the new meta-analyses found no significant benefit for hematoma expansion, mortality, functional outcome, or length of stay, and the guideline therefore makes no recommendation either for or against the drug. Importantly, serious adverse events were similar with and without desmopressin, both in the pooled analyses and in the DASH trial, a randomized, placebo-controlled feasibility study from the United Kingdom that established the safety foundation for a definitive phase III investigation. Both the North American and European guidelines urge enrollment of eligible patients in trials testing desmopressin’s utility, though no such phase III study is currently open. In the interim, Frontera observes that the trend toward less expansion, the demonstrated safety record, the low cost, the mechanistic plausibility, and the absence of alternative hemostatic options for antiplatelet-associated bleeding may reasonably lead practitioners to prescribe it anyway, a rare instance of a guideline update explicitly acknowledging the gap between evidence and bedside reality. The broader message is clear: for traumatic brain injury-related hemorrhage and for hemostatic agents in antiplatelet bleeding, the field still needs well-designed trials before certainty can replace consensus.

Subject of Research: Emergency reversal of antithrombotic therapy in adult intracranial hemorrhage per a 2026 neurocritical care guideline update

Article Title: Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine

Article References: Commentary on: Treatment of Antithrombotic-Associated Intracranial Hemorrhage in Adults: A Focused Guideline Update from the Neurocritical Care Society and Society of Critical Care Medicine. (n.d.). https://doi.org/10.1007/s12028-026-02639-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02639-4

Keywords: intracranial hemorrhage, anticoagulation reversal, andexanet alfa, prothrombin complex concentrate, desmopressin, factor Xa inhibitors, hematoma expansion, Neurocritical Care Society, GRADE methodology, antiplatelet therapy, thromboembolism, viscoelastic testing